Patents Examined by Mindy Newman
-
Patent number: 8802628Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.Type: GrantFiled: August 14, 2009Date of Patent: August 12, 2014Assignees: Ironwood Pharmaceuticals, Inc., Forest Laboratories Holdings, Ltd.Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
-
Patent number: 8791241Abstract: The present invention relates to fluorescent proteins, in particular green fluorescent proteins (GFPs), with increased activity in cells, and thus increased signal strength. A further aspect of the present invention relates to the use of peptides for increasing the expression and/or stability of a protein in a cell.Type: GrantFiled: August 9, 2010Date of Patent: July 29, 2014Assignee: King Faisal Specialist Hospital & Research CentreInventor: Khalid S. Abu Khabar
-
Patent number: 8785376Abstract: In one aspect, the invention relates to isolated compounds useful as antifungal agents, for example, compounds having a structure represented by a formula: wherein R1 is hydrogen or hydroxyl; wherein R2 is hydrogen or xylose; and wherein R3 and R4 are each hydrogen or together oxygen, or a pharmaceutically acceptable salt thereof; methods of isolating and purifying same; pharmaceutical compositions comprising same; agricultural compositions comprising same; and methods of treating and/or preventing fungal infections using same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: December 20, 2011Date of Patent: July 22, 2014Assignees: Virginia Tech Intellectual Properties, University of Utah Research FoundationInventors: Eric W. Schmidt, Joseph O. Falkinham, Peter W. Jeffs
-
Patent number: 8772235Abstract: Described herein are compositions having a peptide sequence that includes at least one bone targeting moiety, wherein the bone targeting moiety is bonded to the peptide sequence by a linker, wherein the peptide sequence is calcitonin, and wherein the composition is neutral or a pharmaceutically acceptable salt or ester thereof. In one aspect, calcitonin inhibits or slows osteoclast mediated resorptive bone loss. The compounds described herein can be used in a number of therapeutic applications including treating or preventing conditions associated with bone loss, which include, but are not limited to, osteoporosis, Paget's disease, osteolytic tumors, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Osteoarthritis, osteopenia, and hypercalcemia. Also described herein are the methods of making these compositions that prevent or treat conditions associated with bone loss and methods of preventing bone fractures.Type: GrantFiled: October 12, 2010Date of Patent: July 8, 2014Assignee: The Governors of the University of AlbertaInventors: Michael R. Doschak, Krishna Hari Bhandari
-
Patent number: 8772230Abstract: This invention relates to the use of niacin and/or trigonelline compounds to increase muscle weight during periods of activity or to inhibit muscle loss during periods of inactivity.Type: GrantFiled: June 10, 2010Date of Patent: July 8, 2014Assignee: DSM IP Assets B.V.Inventors: Angelika Friedel, Karin Kuratli, Christof Wehrli, Karin Wertz, Swen Wolfram, Ying Wang-Schmidt
-
Patent number: 8765682Abstract: The present invention relates to recombinant mussel adhesive protein wherein a DOPA residue is in vivo incorporated instead of a tyrosine residue, and a method for producing the same. More specifically, the present invention relates to recombinant mussel adhesive protein wherein a DOPA residue is incorporated instead of a tyrosine residue, and a method for producing the same, and a transformant for producing the recombinant mussel adhesive protein.Type: GrantFiled: June 14, 2013Date of Patent: July 1, 2014Assignee: Postech Academy-Industry FoundationInventors: Hyung Joon Cha, Byeongseon Yang, Yoo Seong Choi, Hyungdon Yun
-
Patent number: 8748573Abstract: The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions.Type: GrantFiled: August 5, 2010Date of Patent: June 10, 2014Assignee: Ironwood Pharmaceuticals, Inc.Inventors: Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Mahendra Dedhiya, Yun Mo
-
Patent number: 8748564Abstract: The present invention relates to oxytocin receptor agonist compounds, pharmaceutical compositions comprising the same, use of such compounds for the manufacture of a medicament for treatment of inter alia, abdominal pain, irritable bowel syndrome (IBS), autism, erectile dysfunction, female sexual dysfunction, labor induction and maintenance, lactation induction and maintenance, postpartum hemorrhage, Post Traumatic Stress Disorder (PTSD), pain, anxiety and other conditions, as well as to methods for the treatment of such conditions, wherein such compounds are administered.Type: GrantFiled: September 21, 2010Date of Patent: June 10, 2014Assignee: Ferring B.V.Inventors: Kazimierz Wisniewski, Claudio Daniel Schteingart, Sudarkodi Alagarsamy, Robert Galyean
-
Patent number: 8735351Abstract: The invention relates to a method for improving the procoagulant properties of TF expressed in eukaryotic cells by contacting microvesicles derived from said eukaryotic cells with a negatively-charged phospholipid such as phosphatidylserine. The invention also relates to microvesicles obtained using said method as well as to the uses thereof as procoagulant agents, for wound healing and for promoting angiogenesis.Type: GrantFiled: April 19, 2011Date of Patent: May 27, 2014Assignee: Thrombotargets Europe, S.L.Inventors: Jesús Murat Moreno, Juan Ramon Rodriguez Fernández-Alba
-
Patent number: 8729009Abstract: The present invention concerns new thiolysine and selenolysine compounds that can be used as building blocks for peptides and proteins, providing ligation handles for site- and chemoselective modification of said peptides and proteins. In particular, the invention provides. In particular, the invention provides (the use of) the compounds 5-thiolysine (also referred to as ?-thiolysine); 4-thiolysine (also referred to as ?-thiolysine); 5-selenolysine (also referred to as ?-selenolysine) and 4-selenolysine (also referred to as ?-selenolysine). The positioning of the thiol or selenol group at the respective carbon atom allows for a very efficient intramolecular transfer reaction to take place after conjugation with a selected ligand, and the thiol or selenol group may subsequently be removed using reported procedures, thereby restoring the native lysine structure, or be used as an additional conjugation handle. The methodology is fast and gives well-defined material.Type: GrantFiled: May 12, 2010Date of Patent: May 20, 2014Assignee: Stichting Het Nederlands Kanker InstituutInventors: Huib Ovaa, Farid El Oualid
-
Patent number: 8729032Abstract: Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a1b1c1b2a2b3db4a3b5c2b6a4 where: a1 to a4 each represent a basic amino acid residue; b1 to b6 each represent an uncharged polar amino acid residue and/or a hydrophobic amino acid residue, provided that at least five thereof each represent a hydrophobic amino acid residue; c1 and c2 each represent an acidic amino acid residue; and d represents a hydrophobic amino acid residue.Type: GrantFiled: February 12, 2010Date of Patent: May 20, 2014Assignees: Menicon Co., Ltd., National University Corporation Okayama UniversityInventors: Yusuke Nagai, Hidenori Yokoi, Koji Uesugi, Keiji Naruse
-
Patent number: 8703716Abstract: The invention provides methods and compositions for improving fetal and child health and development through nutritional supplementation with, for example, sialic acid. Sialic acid can be provided to a female before, during and/or after pregnancy to improve the health and development of a fetus and/or child. The sialic acid can be in a variety of forms in the supplements.Type: GrantFiled: March 11, 2011Date of Patent: April 22, 2014Assignee: DSM IP Assets B.V.Inventors: John P. Zimmer, Christopher M. Butt
-
Patent number: 8697637Abstract: The present invention relates to an antimicrobial peptide characterised in that said peptide includes the sequence SEQ ID No. 1 or the sequence SEQ ID No. 2, the sequence SEQ ID No. 2 representing a fragment of the sequence SEQ ID No. 1, for use as a drug. Advantageously according to the invention, the peptide having sequence SEQ ID No. 1 is used specifically for treating bacterial, viral and/or parasitic infections, and the peptide having sequence SEQ No. 2 is used for treating bacterial and/or viral infections.Type: GrantFiled: February 3, 2011Date of Patent: April 15, 2014Assignee: Institut de Recherche pour le Developpement (IRD)Inventors: Marthe Dorothée Misse Brumas, Natthanej Luplertlop, Hans Yssel, Frédéric Thomas, François Renaud
-
Patent number: 8697649Abstract: A polypeptide, a nucleic acid molecule encoding the polypeptide and a pharmaceutical composition comprising the polypeptide are provided. The polypeptide is as defined in the description, can bind to insulin receptors, and is effective in reducing blood sugar, reducing glycated hemoglobin, and ameliorating hepato-renal disorders caused by diabetes.Type: GrantFiled: July 25, 2012Date of Patent: April 15, 2014Assignee: China Medical UniversityInventors: Tin-Yun Ho, Chien-Yun Hsiang
-
Patent number: 8691195Abstract: The present invention relates to a transforming growth factor-beta (TGF-?)-mimicking peptide containing a particular amino acid sequence and a composition for preventing or treating TGF-?-effective disorders or conditions using the same. The peptide of the present invention may be much higher stability than natural-occurring TGF-? and improve drawbacks caused by high molecular weight of natural-occurring TGF-?. The peptide of this invention can be advantageously applied to treatment or improvement of TGF-?-effective disorders or conditions and have excellent efficacies on skin whitening and wrinkle improvement.Type: GrantFiled: April 14, 2009Date of Patent: April 8, 2014Assignee: Caregen Co., Ltd.Inventors: Young Ji Chung, Young Deug Kim, Eun Mi Kim, Jeong Jin Choi, Jun Young Choi
-
Patent number: 8680045Abstract: This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.Type: GrantFiled: November 1, 2011Date of Patent: March 25, 2014Assignee: PeptiMed, Inc.Inventors: Thomas Primiano, Bey-Dih Chang, Jeremy Heidel
-
Patent number: 8673849Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antiviral activity, particularly against integrin-using viruses, more particularly against rotavirus. Further, the present invention refers to compositions comprising said peptidic compounds for medical use or for use as food additives.Type: GrantFiled: May 31, 2011Date of Patent: March 18, 2014Assignee: ROTALACTIS SrlInventors: Amedeo Conti, David Lembo, Claudio Fabris, Enrico Bertino, Santo Landolfo
-
Patent number: 8673986Abstract: The present invention relates to a coacervate comprising a mussel adhesive protein and an anionic polymer, and more particularly, to a coacervate prepared by mixing a mussel adhesive protein with an anionic polymer, and a novel use thereof. In the present invention, a coacervate prepared by mixing a mussel adhesive protein and an anionic polymer shows a very excellent adhesive strength to various substrates such as cells or metals, and is able to maintain its adhesive strength in the presence of water or under water, thereby being effectively used as an adhesive. Moreover, it has an activity capable of encapsulating bioactive materials, thereby being effectively used as an active component of a composition for delivering bioactive materials.Type: GrantFiled: August 6, 2010Date of Patent: March 18, 2014Assignee: Postech Academy-Industry FoundationInventors: Hyung Joon Cha, Yoo Seong Choi, Dong Gyun Kang, Young Hoon Song, Seonghye Lim, Bong-Hyuk Choi
-
Patent number: 8673848Abstract: The invention provides a synthetic polypeptide of Formula I?: or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia.Type: GrantFiled: January 23, 2013Date of Patent: March 18, 2014Assignee: Novartis AGInventors: Frédéric Zecri, Andrei Golosov, Philipp Grosche, Kayo Yasoshima, Hongjuan Zhao, Qi-Ying Hu, Hidetomo Imase, David Thomas Parker
-
Patent number: 8673847Abstract: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.Type: GrantFiled: October 5, 2010Date of Patent: March 18, 2014Assignee: The Medical College of Wisconsin, Inc.Inventors: Hao Zhang, Yang Shi, Hao Xu, Kirkwood A. Pritchard, Jr.